# EDGAR Filing Document

**Accession Number:** 0001262104
**File Stem:** 0001193125-25-290059
**Filing Date:** 2025-11
**Character Count:** 6691
**Document Hash:** 73819987e5ff076d52c408389e450511
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-290059.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001193125-25-290059

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20251114

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lite Strategy, Inc.
- **CENTRAL INDEX KEY:** 0001262104
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 510407811
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41827
- **FILM NUMBER:** 251504027

**BUSINESS ADDRESS:**
- **STREET 1:** 9920 PACIFIC HEIGHTS BLVD
- **STREET 2:** SUITE 150
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-369-7100

**MAIL ADDRESS:**
- **STREET 1:** 9920 PACIFIC HEIGHTS BLVD
- **STREET 2:** SUITE 150
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MEI Pharma, Inc.
- **DATE OF NAME CHANGE:** 20120629

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARSHALL EDWARDS INC
- **DATE OF NAME CHANGE:** 20030902

?xml version='1.0' encoding='ASCII'? 8-K/A

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

------

## FORM 8-K/A

## Amendment No. 1

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** November 14, 2025<br>

------

Lite Strategy, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-41827 | 51-0407811 |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 9920 Pacific Heights Blvd.,<br>Suite 150 |  |  |
| San Diego**,** California |  | 92121 |
| **(Address of principal executive Offices)** |  | **(Zip Code)** |

---

**Registrant's telephone number, including area code:** 858 369-7100<br>

**(Former name or former address, if changed since last report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.00000002 par value | LITS | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Explanatory Note**

This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 18, 2025 (the Original Form 8-K) by Lite Strategy, Inc. (the Company), to correct information regarding the number of shares of the Company's common stock $0.00000002 par value (the Common Stock), issuable upon the exercise of stock options granted to Justin J. File on such date in connection with his appointment as Chief Executive Officer of the Company.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

In the Original Form 8-K, the Company reported that the Board of Directors (the Board) granted Mr. File options (the Options) to purchase 635,000 shares of the Common Stock under the Company's Amended and Restated 2008 Stock Omnibus Equity Compensation Plan (the Equity Plan). The actual number of shares of Common Stock issuable upon exercise of the options granted to Mr. File was 180,000 shares.

On November 20, 2025, the Board approved a grant to Mr. File of options (the Replacement Options) to purchase 455,000 shares of Common Stock, with such options to have an exercise price per share equal to the greater of (a) the closing price of the Common Stock on Nasdaq on the date of grant and (b) $2.02 (which is the exercise price per share of the Options granted on November 14, 2025). The closing price of the Common Stock on Nasdaq on November 20, 2025 was $1.70, and the Replacement Options thus have an exercise price per share of $2.02. The Replacement Options otherwise have the same terms as, and shall vest on the same schedule as, the options to purchase 180,000 shares of Common Stock granted to Mr. File on November 14, 2025; provided that the Replacement Options shall be granted under, and subject to and contingent upon approval by the Company's stockholders of, a new omnibus equity plan to replace the Equity Plan (the New Omnibus Plan), and the Replacement Options shall be cancelled if the New Omnibus Plan is not approved by the Company's stockholders at the annual meeting of stockholders for the fiscal year 2026.

Except as described above, no other changes have been made to the Original Form 8-K, and this amendment does not modify or update any other information contained in the Original Form 8-K. This amendment should be read in conjunction with the Original Form 8-K.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | LITE STRATEGY, INC. |
| Date: | November 20, 2025 | By:  | /s/ Justin J. File |
|  |  |  | Chief Executive Officer, Chief Financial Officer and Secretarty |

---

------